Sat, Jul 12, 2014, 2:41 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • rapp78 rapp78 Aug 20, 2013 10:12 PM Flag

    MNKD Setting Themselves Up for Another Class Action?

    MNKD is currently finalizing a class action settlement where they are potentially paying out $16 million in cash and over 1.7 million shares for allegations that "MannKind Corp and certain of its officers and directors violated between June 25, 2010 and January 19, 2011 the Securities Exchange Act of 1934 by issuing materially false and misleading statements regarding its business and prospects for AFREZZA."

    During the cc last week MNKD was asked what the Medtone A1c levels were. Bob dodged the question and said "all I can tell you is that they were comparable . . '.

    When the main purpose of these trials is to prove bio = and MNKD refuses to release the single most important data point to prove or disprove bio =, it creates an information gap and leads to manipulation. But is withholding that data also materially false and misleading?

    The trial design for 171 is for safety and EFFICACY, measured by HbA1c's for all THREE arms. Yet they refuse to provide the A1c of one of the arms when specifically asked? How can investors do proper DD?

    Do they know the MT results are so superior to DB that it will disprove bio = of the two inhalers? More importantly, are they intentionally withholding this info after calling these trials a "success"? Al Mann said in Q3 earnings release that bridging data and comparing "glycemic effects" of the inhalers vs. raa were the major objectives of 171. Yet they refuse to release the best indicator of "glycemic effects" and bio = of the two inhalers?

    Also, in June, Mann says the FDA requires "greater than .5 more than placebo" to meet the primary endpoints in 175, only to change it to .4 AFTER results. During cc Bob says they "assumed" a .5 was needed but were wrong. Do they think we're stupid? You have billions on the line and you don't know if the FDA requires "greater than .5" or just a .4 for your largest market?

    Something isn't passing the smell test here. Traders/Investors/potential partners should be demanding answers.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MNKD
10.07+0.18(+1.82%)Jul 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.